fbpx

Year

2015
Lund, Sweden, (PRNEWSWIRE) June 23, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, is pleased to announce that a recent study entitled, A Biphasic Apatite/Sulphate Bone Substitute, CERAMENTT Induces Bone In a Skeletal Muscle Cell Line, was awarded with the EFORT...
Lundbeck Foundation Professor Eske Willerslev solves a Scientific controversy about the Kennewick Man. 
Gaithersburg, MD, June 15, 2015 - Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) and the filling of a key staff position in patient advocacy.  
Modern European and Central Asian peoples are genetically speaking not more than a couple of thousand years old. It was during the Bronze Age that the last major chapters were written in the story of the genetic past of Europe and central Asia. How it happened has been intensively debated among archaeologists.
CANTERBURY, UK, 10 JUNE, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced that it has dosed the first patient in its Phase 2a proof-of-concept clinical trial of ZPL-389 in patients with moderate to severe atopic dermatitis at MAC Clinical Research in Manchester, UK. ZPL-389 is the Company's novel, once-daily,...
CANTERBURY, UK, 8 JUNE, 2015 -- Ziarco Group Ltd., a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Pablo Jimenez, M.D., as Chief Medical Officer, effective immediately. Dr. Jimenez will oversee the clinical development of Ziarco's programs targeting conditions such as atopic dermatitis and psoriasis.
Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.CAMBRIDGE, Mass.- June 8, 2015 -  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing.  Lundbeckfond Ventures led the round as a...
Pivotal Rat Study Presented at 2015 Orthopedic Research Society Annual Meeting  Lund, Sweden, (PRNEWSWIRE) May 27, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENTT'G as presented at the 2015 Orthopedic Research Society...
OXFORD, UK - 19 May 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody 'armed' series of AbEnAd viruses.
South San Francisco, CA - May 12, 2015 - Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director...
1 2 3 4 5 6 7

News

Danish researchers provide proof: Caesarean sections can lead to asthma and allergies
12. November 2020
Brand-new medical treatment for cocaine addiction
10. November 2020
90 million to 18 Talented Researchers
19. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge